Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/13993003.00547-2020 http://scihub22266oqcxt.onion/10.1183/13993003.00547-2020 32217650!7098485!32217650     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Respir+J 2020 ; 55 (5): ä Nephropedia Template TP {{tp|p=32217650|t=2020. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis |pdf=|usr=}}{{32217650}} gab.com Text Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis JO: Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=32217650 #FOAvip BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. OBJECTIVE: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. METHODS: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. RESULTS: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.03-2.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61-4.17) among patients with two or more comorbidities. CONCLUSION: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes. Twit Text FOAVip Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis ????Eur Respir J http://www.kidney.de/pget.php?&tw=1&pmid=32217650 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32217650 #FOAvip English Wikipedia <ref>{{Cite pmid|32217650}}</ref> Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis #MMPMID32217650 Guan WJ; Liang WH; Zhao Y; Liang HR; Chen ZS; Li YM; Liu XQ; Chen RC; Tang CL; Wang T; Ou CQ; Li L; Chen PY; Sang L; Wang W; Li JF; Li CC; Ou LM; Cheng B; Xiong S; Ni ZY; Xiang J; Hu Y; Liu L; Shan H; Lei CL; Peng YX; Wei L; Liu Y; Hu YH; Peng P; Wang JM; Liu JY; Chen Z; Li G; Zheng ZJ; Qiu SQ; Luo J; Ye CJ; Zhu SY; Cheng LL; Ye F; Li SY; Zheng JP; Zhang NF; Zhong NS; He JX Eur Respir J 2020[May]; 55 (5): ä PMID32217650show ga BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide. OBJECTIVE: To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status. METHODS: We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities. RESULTS: The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424-5.048)), diabetes (1.59 (1.03-2.45)), hypertension (1.58 (1.07-2.32)) and malignancy (3.50 (1.60-7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16-2.77) among patients with at least one comorbidity and 2.59 (1.61-4.17) among patients with two or more comorbidities. CONCLUSION: Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes. |*Betacoronavirus[MESH] |Adult[MESH] |COVID-19[MESH] |China/epidemiology[MESH] |Comorbidity[MESH] |Coronavirus Infections/diagnosis/*epidemiology[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*epidemiology[MESH] |Prognosis[MESH] |Risk Factors[MESH]Comorbidity and its impact on 1590 patients with COVID-19 in China: a (epmc).pdf DeepDyve Pubget Overpricing